A new phase 3 study, led by Scott Kopetz and an international team, provides strong evidence supporting encorafenib + cetuximab (EC) with mFOLFOX6 as a first-line treatment for BRAF V600E-mutant metastatic colorectal cancer (mCRC). The BREAKWATER trial compared EC+mFOLFOX6 against standard chemotherapy, demonstrating a significant and durable improvement in response rates.
Key findings:
Objective response rate: 60.9% (EC+mFOLFOX6) vs. 40.0% (standard care), p=0.0008
Median duration of response: 13.9 vs. 11.1 months
Interim overall survival analysis: HR=0.47, indicating a promising trend
Safety profile consistent with known effects of each agent
These results mark an important step toward refining treatment for BRAF-mutant mCRC, a population with historically poor outcomes on standard chemotherapy.
The contributions of Takayuki Yoshino, Eric Van Cutsem,Cathy Eng, Josep Tabernero MD, PhD, and the entire research team have been instrumental in advancing therapeutic strategies for this high-risk subgroup.
Read the full study here: https://lnkd.in/edVCiqCR
